Obudanersen

RNA / oligonucleotide

Phase 3underway

Evidence outlook · registrational

Angelman Syndrome: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-08.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Angelman Syndrome
Phase 1/2 (1)
Angelman Syndrome

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Obudanersen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
Phase 3Angelman SyndromeActive not recruiting
Est. primary completion 2027-08 · NCT06914609 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 3Angelman SyndromeRecruiting
Est. primary completion 2028-05 · NCT07782827 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Phase 1/2Angelman SyndromeActive not recruiting
Est. primary completion 2032-03 · NCT05127226 · CT.gov ↗
What to watch

See the full readout calendar ↗